Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis
- 23 October 2000
- reference entry
- review article
- Published by Wiley
- No. 4,p. CD002009
- https://doi.org/10.1002/14651858.cd002009
Abstract
Patients with cystic fibrosis, who are chronically colonised with the organism Pseudomonas aeruginosa, often require repeated courses of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations. The properties of aminoglycosides suggest that they could be given in higher concentrations less often. To assess the effectiveness and safety of once-daily versus multiple-daily dosing of intravenous aminoglycoside antibiotics for the management of pulmonary exacerbations in cystic fibrosis. We searched the Cystic Fibrosis specialist trials register held at the Cochrane Cystic Fibrosis and Genetic Disorders Group's editorial base, which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and handsearching abstract books of conference proceedings. Date of the most recent search: February 2000. All randomised controlled trials, whether published or unpublished, in which once-daily dosing of aminoglycosides has been compared with multiple-daily dosing in terms of efficacy and/or toxicity, in patients with cystic fibrosis. Both reviewers independently extracted data and assessed trial quality. Authors of one study were contacted to obtain missing information. Two trials reporting results from a total of 70 patients were included in this review. Both trials compared once-daily dosing with thrice-daily dosing reporting data on Forced Expiratory Volume at one second (FEV1), Forced Vital Capacity (FVC), nutritional status and side effects. There was no significant difference in efficacy or in the incidence of ototoxicity and nephrotoxicity between treatment groups. Despite a lack of difference between the two groups we feel that these results should be viewed with caution as the numbers of patients involved was small and lacks the power to detect a difference between the groups. This systematic review has highlighted the need for a well designed, adequately-powered, multicentre, randomised controlled trial assessing the efficacy of once-daily versus multiple-daily dosing of intravenous aminoglycosides for pulmonary exacerbations in cystic fibrosis.This publication has 19 references indexed in Scilit:
- 51. Efficacy and safety of once daily tobramycin in treating acute respiratory exacerbations in adult patientsStroke Prevention in Atrial Fibrillation, 1999
- Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosisArchives of Disease in Childhood, 1998
- Cystic fibrosis.American Journal of Respiratory and Critical Care Medicine, 1996
- Trials to assess equivalence: the importance of rigorous methodsBMJ, 1996
- Minimisation of aminoglycoside toxicity in patients with cystic fibrosis.Thorax, 1996
- Single or multiple daily doses of aminoglycosides: a meta- analysisBMJ, 1996
- Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosaAntimicrobial Agents and Chemotherapy, 1995
- Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patientsThe Pediatric Infectious Disease Journal, 1991
- Antibiotic Pharmacokinetics in Cystic FibrosisClinical Pharmacokinetics, 1987
- Once-Daily vs. Continuous Aminoglycoside Dosing: Efficacy and Toxicity in Animal and Clinical Studies of Gentamicin, Netilmicin, and TobramycinThe Journal of Infectious Diseases, 1983